ENTX Entera Bio Ltd.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1638097 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-76.8%
TTM net income YoY-19.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-32.1%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-27,450.0%
Net margin-27,235.7%
FCF margin-17,802.4%
EBITDA margin-27,378.6%
Returns
ROE-108.0%
ROA-90.1%
ROIC (approx.)-341.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.1%
Debt / equity0.00x
Current ratio6.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-32.1%
Payout ratio—
Capex / revenue254.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $42,000 | $82,000 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $42,000 | $82,000 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $4.92M | $3.20M | $2.25M | $1.72M | $1.64M | $1.52M | $1.12M | $1.20M |
| SG&A expense | $157,000 | $124,000 | $128,000 | $54,000 | $118,000 | $103,000 | $123,000 | $96,000 |
| Operating income | -$7.26M | -$4.56M | -$3.54M | -$3.04M | -$3.26M | -$2.67M | -$2.56M | -$2.34M |
| Pretax income | — | — | — | — | — | — | — | -$2.34M |
| Income tax | — | — | — | — | — | — | — | $14,000 |
| Net income | -$15.60M | -$7.31M | -$3.50M | -$3.02M | -$3.20M | -$2.66M | -$2.57M | -$2.36M |
| EBITDA | -$7.26M | -$4.55M | -$3.53M | -$3.04M | -$3.25M | -$2.66M | -$2.56M | -$2.33M |
| EPS (basic) | 0.11 | 0.14 | 0.07 | — | 0.07 | 0.06 | 0.06 | — |
| EPS (diluted) | 0.11 | 0.14 | 0.07 | — | 0.07 | 0.06 | 0.06 | — |
| Weighted avg. shares (diluted) | 145.08M | 50.45M | 47.76M | — | 47.09M | 46.84M | 43.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $265.88M | $11.31M | $4.14M | $7.11M | $8.57M | $10.86M | $12.57M | $8.74M |
| Receivables | — | — | — | $0 | $0 | $0 | $126,000 | $126,000 |
| Current assets | $276.46M | $18.90M | $12.49M | $15.30M | $17.01M | $19.31M | $21.22M | $8.97M |
| PP&E, net | $133,000 | $121,000 | $127,000 | $134,000 | $114,000 | $79,000 | $57,000 | $57,000 |
| Total assets | $277.04M | $19.48M | $13.13M | $15.99M | $17.41M | $19.67M | $21.60M | $9.39M |
| Current liabilities | $2.15M | $2.10M | $1.58M | $2.20M | $1.57M | $1.84M | $1.62M | $1.18M |
| Total liabilities | $2.76M | $12.21M | $2.44M | $2.89M | $2.17M | $2.41M | $2.22M | $1.31M |
| Shareholders' equity | $274.28M | $7.27M | $10.69M | $13.10M | $15.23M | $17.26M | $19.38M | $8.08M |
| Shares outstanding | 173.92M | 49.29M | 46.62M | 46.18M | 45.66M | 45.45M | 45.42M | 38.84M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.40M | -$3.46M | -$3.09M | -$1.83M | -$2.50M | -$1.63M | -$1.40M | -$1.47M |
| Capital expenditure | $21,000 | $3,000 | $0 | $27,000 | $43,000 | $29,000 | $8,000 | $3,000 |
| Free cash flow | -$7.42M | -$3.47M | -$3.09M | -$1.86M | -$2.54M | -$1.66M | -$1.41M | -$1.47M |
| Investing cash flow | -$21,000 | -$3,000 | $0 | -$27,000 | -$43,000 | -$29,000 | -$8,000 | -$3,000 |
| Financing cash flow | $261.41M | $9.96M | $130,000 | $174,000 | $250,000 | -$51,000 | $13.34M | $3.22M |
| Depreciation & amortization | $9,000 | $9,000 | $7,000 | $7,000 | $8,000 | $7,000 | $8,000 | $11,000 |
| Stock-based compensation | $1.82M | $624,000 | $672,000 | $710,000 | $927,000 | $509,000 | $604,000 | $566,000 |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.